|Bid||0.000 x 0|
|Ask||0.000 x 0|
|Day's Range||54.050 - 54.200|
|52 Week Range||45.570 - 55.320|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.40%|
In August 2017, the FDA approved Teva Pharmaceutical's (TEVA) Austedo for the treatment of adult individuals with tardive dyskinesia.
Value stocks in the United States are scuffling against broader benchmarks and growth stocks. While ex-US developed markets value stocks are also trailing relevant benchmarks, the value factor is performing ...